JP6259208B2 - Hyaluronic acid production promoter - Google Patents

Hyaluronic acid production promoter Download PDF

Info

Publication number
JP6259208B2
JP6259208B2 JP2013126446A JP2013126446A JP6259208B2 JP 6259208 B2 JP6259208 B2 JP 6259208B2 JP 2013126446 A JP2013126446 A JP 2013126446A JP 2013126446 A JP2013126446 A JP 2013126446A JP 6259208 B2 JP6259208 B2 JP 6259208B2
Authority
JP
Japan
Prior art keywords
hyaluronic acid
lipocalin
acid production
production promoter
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013126446A
Other languages
Japanese (ja)
Other versions
JP2015000038A (en
Inventor
高野 義彦
義彦 高野
晴彦 加藤
晴彦 加藤
宏 上野
宏 上野
敏也 小林
敏也 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Priority to JP2013126446A priority Critical patent/JP6259208B2/en
Priority to PCT/JP2014/066000 priority patent/WO2014203883A1/en
Publication of JP2015000038A publication Critical patent/JP2015000038A/en
Application granted granted Critical
Publication of JP6259208B2 publication Critical patent/JP6259208B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • A23L2/66Proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Non-Alcoholic Beverages (AREA)

Description

本発明は、皮膚の荒れ、シワ、弾性低下、関節機能低下等を防止するのに有用なヒアルロン酸産生促進剤、ヒアルロン酸産生促進用サプリメント、飲食品及びヒアルロン酸産生促進用化粧料に関する。   The present invention relates to hyaluronic acid production promoters, hyaluronic acid production promoting supplements, foods and drinks, and hyaluronic acid production promoting cosmetics that are useful for preventing rough skin, wrinkles, reduced elasticity, reduced joint function, and the like.

近年、光老化という、長年において肌に紫外線が照射され続けることによる、しみ、皺、たるみなどの肌の障害を防止することに関して、多くの研究がなされている。
皮膚はおおまかに皮膚表面に存在する表皮と表皮の下部に存在する真皮からなる。表皮は主に外部からの異物や病原菌、紫外線から保護するバリアー機能や、生体内からの物質の漏洩を防護する機能を有する。また真皮は表皮の約15〜40倍の厚さを持ち、皮膚の力学的強度を保つ役割を担っている。真皮はその乾燥重量の70%がコラーゲンからなる繊維成分であるが、真皮の線維と皮膚線維芽細胞との間には、糖蛋白質や、プロテオグリカンといった基質が存在する。プロテオグリカンは、糖蛋白質とグリコサミノグリカンといったムコ多糖とが結合した分子量10〜10以上の巨大分子であり、真皮のグリコサミノグリカンは、主にヒアルロン酸やデルマタン硫酸からなるため、ヒアルロン酸は真皮における主要なマトリックス成分であると言える。
老化などの生理的要因や、太陽光などの紫外線、乾燥、酸化等などの外的環境の変化により皮膚の水分含量や真皮のヒアルロン酸量が低下すると、皮膚に皺が発生し、たるんだ状態を引き起こす。ヒアルロン酸は、主に皮膚の水分を保持する機能を有していることから、真皮中のヒアルロン酸含量を高めることによって、皮膚の水分含量の低下を防ぐことができると考えられ、皮膚における水分保持機能の改善剤として、ヒアルロン酸を配合した化粧料が数多く提案されている。しかしながら、これらは皮膚表面に塗布されたヒアルロン酸は、皮膚表面の保湿効果を発揮するのみであり、肌の機能低下を本質的に改善し得るものではない。
体内のヒアルロン酸を増加させる為に、ヒアルロン酸を経口摂取する方法がある。しかし、ヒアルロン酸は、高い相対分子量や低い脂溶性、生体膜障壁の通過困難性、大量の多糖分解酵素の存在といった理由から、経口投与した際の消化管からの吸収が悪い。ヒアルロン酸の吸収増進のために、特許文献1では、ヒアルロン酸とリン脂質の複合体が提案されている。しかし、ヒアルロン酸を経口摂取せずに体内のヒアルロン酸を増加させる方法はなんら開示されていない。
そこで、肌の機能低下を本質的に改善するために、真皮層のヒアルロン酸の生合成を促進させる必要があり、これによって皮膚のシワやたるみを防止できるヒアルロン酸産生促進剤が望まれていた。
ヒアルロン酸産生促進剤としてはアマチャヅル、カンラン化ボスウェリア属フランキンセンス、ビャクダン科ビャクダン属ビャクダン、バラ科バラ属ダマスクロ−ズ、シソ科マンネンロウ属ロ−ズマリ−から得られる抽出物が開示されている。(特許文献1,2)
一方、関節液中のヒアルロン酸は、関節軟骨の表面を覆い、関節機能の円滑な作動に役立っている。正常人関節液中のヒアルロン酸濃度は約2.3mg/mLであるが、例えば、関節リウマチの場合、関節液中のヒアルロン酸濃度は約1.2mg/mLへと低下し、同時に関節液の粘度も著しく低下する。また、化膿性関節炎や痛風性関節炎などでも関節リウマチの場合と同様、ヒアルロン酸含量の低下が起こることが知られている(非特許文献1)。
上記疾患において、潤滑機能の改善、関節軟骨の被覆・保護、疼痛抑制及び病的関節液の性状改善をするために、関節液中のヒアルロン酸量を増加させることが行われている。例えば、関節リウマチ患者にヒアルロン酸ナトリウムの関節注入療法を行うと、上記の改善が認められている(非特許文献2)。同様に、外傷性関節症、骨関節炎や変形性関節症においても、ヒアルロン酸の関節注入療法による改善効果が報告されている(非特許文献3)。
以上のことから、ヒアルロン酸産生の促進は、肌荒れ等の皮膚疾患、関節リウマチや外傷性関節症、骨関節炎、変形性関節症といった関節疾患の予防、治療に有効である。したがって、日常の生活の中で手軽に治療できるヒアルロン酸産生促進剤を含有するサプリメント、クリームあるいは飲食品が望まれていた。
リポカリン2(LCN2)及びβラクトグロブリンは、8本のβ−バレル構造を有するリポカリンファミリーに属するタンパク質である。
リポカリン2(LCN2)は、ヒト好中球ゼラチナーゼ結合性リポカリン(NGAL)とも呼ばれ、92kDaのヒト好中球タイプIVコラゲナーゼに結合するタンパク質として同定されている。肝臓から分泌されるリポカリン2は、ジデロフォア−Fe3+と選択的に結合することで、バクテリアの鉄利用を阻害し増殖を阻害するといった抗菌作用を持つ。また、血漿、血中のリポカリン2が炎症や感染のマーカーとして、尿中のリポカリン2が乳がんなどの悪性腫瘍のマーカーとして利用できるとの報告がある。リポカリン2は、牛乳中にも含まれることが知られているが、成熟乳に比べて初乳中に多く含まれるとの報告がある。しかしながら牛乳中のリポカリン2の機能についての報告はない。
βラクトグロブリンは牛乳中の主要な乳清タンパク質である。有用生理活性物質であるレチノール等の疎水性物質の結合能を有しており、優れた機能特性(乳化性、ゲル化性、起泡性)を有する。
In recent years, much research has been conducted on photoaging, which is to prevent skin disorders such as spots, wrinkles, and sagging caused by long-term irradiation of ultraviolet rays on the skin.
The skin is roughly composed of the epidermis present on the skin surface and the dermis present in the lower part of the epidermis. The epidermis mainly has a barrier function that protects against foreign substances, pathogenic bacteria, and ultraviolet rays, and a function that protects the leakage of substances from the living body. The dermis has a thickness about 15 to 40 times that of the epidermis and plays a role in maintaining the mechanical strength of the skin. The dermis is a fiber component comprising 70% of the dry weight of collagen, but a substrate such as glycoprotein or proteoglycan exists between dermis fibers and skin fibroblasts. Proteoglycan is a macromolecule having a molecular weight of 10 5 to 10 6 or more in which a glycoprotein and a mucopolysaccharide such as glycosaminoglycan are combined. Glycosaminoglycan in the dermis is mainly composed of hyaluronic acid or dermatan sulfate. It can be said that acid is the main matrix component in the dermis.
If the skin moisture content or the amount of hyaluronic acid in the dermis decreases due to physiological factors such as aging, or changes in the external environment such as ultraviolet rays such as sunlight, dryness, oxidation, etc., wrinkles occur in the skin and it becomes dull cause. Hyaluronic acid mainly has a function of retaining the moisture of the skin, so it is considered that the decrease of the moisture content of the skin can be prevented by increasing the hyaluronic acid content in the dermis. Many cosmetics containing hyaluronic acid have been proposed as an improving agent for the retention function. However, the hyaluronic acid applied to the skin surface only exhibits a moisturizing effect on the skin surface, and cannot essentially improve the skin functional deterioration.
In order to increase hyaluronic acid in the body, there is a method of ingesting hyaluronic acid orally. However, hyaluronic acid is poorly absorbed from the digestive tract when administered orally because of its high relative molecular weight, low fat solubility, difficulty in passage through biological membrane barriers, and the presence of large amounts of polysaccharide-degrading enzymes. In order to enhance the absorption of hyaluronic acid, Patent Document 1 proposes a complex of hyaluronic acid and phospholipid. However, no method for increasing hyaluronic acid in the body without ingesting hyaluronic acid is disclosed.
Therefore, in order to essentially improve the functional deterioration of the skin, it is necessary to promote the biosynthesis of hyaluronic acid in the dermis layer, and thus a hyaluronic acid production promoter that can prevent skin wrinkles and sagging has been desired. .
As hyaluronic acid production promoters, extracts obtained from hamachal, kanranized Boswellia genus frankincense, sandalwood family sandalwood genus sandalwood, rose family rose genus damask rose, perilla family mannenro genus rosemary are disclosed. (Patent Documents 1 and 2)
On the other hand, hyaluronic acid in synovial fluid covers the surface of articular cartilage and helps smooth operation of joint functions. The concentration of hyaluronic acid in normal human joint fluid is about 2.3 mg / mL. For example, in the case of rheumatoid arthritis, the concentration of hyaluronic acid in joint fluid decreases to about 1.2 mg / mL, and at the same time, The viscosity is also significantly reduced. Also, it is known that hyaluronic acid content decreases in pyogenic arthritis and gouty arthritis as in the case of rheumatoid arthritis (Non-patent Document 1).
In the above diseases, the amount of hyaluronic acid in the joint fluid is increased in order to improve the lubrication function, cover / protect articular cartilage, suppress pain, and improve the properties of pathological joint fluid. For example, when rheumatoid arthritis patients are given joint injection therapy with sodium hyaluronate, the above improvement has been observed (Non-patent Document 2). Similarly, also in traumatic arthropathy, osteoarthritis and osteoarthritis, the improvement effect by joint injection therapy of hyaluronic acid has been reported (Non-patent Document 3).
From the above, promotion of hyaluronic acid production is effective for the prevention and treatment of skin diseases such as rough skin, joint diseases such as rheumatoid arthritis, traumatic arthropathy, osteoarthritis, and osteoarthritis. Therefore, a supplement, cream or food or drink containing a hyaluronic acid production promoter that can be easily treated in daily life has been desired.
Lipocalin 2 (LCN2) and β-lactoglobulin are proteins belonging to the lipocalin family having eight β-barrel structures.
Lipocalin 2 (LCN2), also called human neutrophil gelatinase-binding lipocalin (NGAL), has been identified as a protein that binds to a 92 kDa human neutrophil type IV collagenase. Lipocalin 2 secreted from the liver has an antibacterial action by selectively binding to diderophore-Fe 3+ to inhibit bacterial iron utilization and growth. In addition, it has been reported that lipocalin 2 in plasma and blood can be used as a marker for inflammation and infection, and lipocalin 2 in urine can be used as a marker for malignant tumors such as breast cancer. Lipocalin 2 is known to be also contained in milk, but it has been reported that it is more contained in colostrum than in mature milk. However, there is no report about the function of lipocalin 2 in milk.
β-lactoglobulin is the major whey protein in milk. It has the ability to bind hydrophobic substances such as retinol, which is a useful physiologically active substance, and has excellent functional properties (emulsifying property, gelling property, foaming property).

特開 2007−51091JP 2007-51091 A 特開 2013−23437JP 2013-23437

The Lancet,第351巻,197頁,1998年The Lancet, 351, 197, 1998 Rheumatology International,第22巻,4号,2002年Rheumatology International, Vol. 22, No. 4, 2002 Canadian Medical Association Juornal,第172巻,8号,1039頁,2005年Canadian Medical Association Journal, 172, 8, 1039, 2005

特許文献1,2に開示されている発明では、植物由来の原材料を用いる為、ヒアルロン酸産生促成剤の原料の栽培が特定の地域に限られていたり、季節による供給の変動が大きいなど安定供給が出来ないという課題がある。そこで、本発明は、経口摂取可能なヒアルロン酸産生促進剤を提供すること及び、そのような物質を配合したヒアルロン酸産生促進用サプリメント、飲食品及びヒアルロン酸産生促進用化粧料を提供することを課題とする。   In the inventions disclosed in Patent Literatures 1 and 2, because plant-derived raw materials are used, stable supply such as cultivation of hyaluronic acid production promoter raw materials is limited to a specific region, and fluctuations in supply due to the season are large. There is a problem that cannot be done. Therefore, the present invention provides a hyaluronic acid production promoter that can be taken orally, and provides a supplement for promoting hyaluronic acid production, a food and drink, and a cosmetic for promoting hyaluronic acid production containing such substances. Let it be an issue.

本発明者らは、これらの課題を解決するために、ヒアルロン酸産生促進作用を示す物質について、鋭意、探索を進めたところ、リポカリンファミリータンパク質あるいはリポカリンファミリータンパク質を分解して得られるリポカリンファミリータンパク質分解物が、ヒアルロン酸産生量を増加させることを見出し、本発明を完成するに至った。
すなわち本発明は、以下の態様を含むものである。
(1)リポカリンファミリー及び/又はリポカリンファミリー分解物を有効成分とするヒアルロン酸産生促進剤。
(2)上記リポカリンファミリー及び/又はリポカリンファミリー分解物が、リポカリン2及び/又はリポカリン2分解物である、(1)記載のヒアルロン酸産生促進剤。
(3)上記リポカリンファミリー及び/又はリポカリンファミリー分解物が、βラクトグロブリン及び/又はβラクトグロブリン分解物である、(1)記載のヒアルロン酸産生促進剤。
(4)前記リポカリン2分解物が、分子量300以上、8000以下であることを特徴とする(2)に記載のヒアルロン酸産生促進剤。
(5)前記リポカリン2分解物が、リポカリン2をタンパク質分解酵素で分解して得られたものであることを特徴とする(2)記載のヒアルロン酸産生促進剤。
(6)前記タンパク質分解酵素が、トリプシン、パンクレアチン、キモトリプシン、ペプシン、パパイン、カリクレイン、カテプシン、サーモライシン、V8プロテアーゼから選択されるいずれか1種以上であることを特徴とする(5)記載のヒアルロン酸産生促進剤。
(7)(1)〜(6)のいずれかに記載のヒアルロン酸産生促進剤を配合したサプリメント。
(8)(1)〜(6)のいずれかに記載のヒアルロン酸産生促進剤を配合した飲食品。
(9)(1)〜(6)のいずれかに記載のヒアルロン酸産生促進剤を配合した化粧料。
In order to solve these problems, the present inventors diligently searched for a substance exhibiting hyaluronic acid production promoting action. As a result, lipocalin family protein degradation obtained by degrading lipocalin family protein or lipocalin family protein was investigated. The product has been found to increase the amount of hyaluronic acid produced, and the present invention has been completed.
That is, the present invention includes the following aspects.
(1) A hyaluronic acid production promoter containing a lipocalin family and / or a lipocalin family degradation product as an active ingredient.
(2) The hyaluronic acid production promoter according to (1), wherein the lipocalin family and / or lipocalin family degradation product is lipocalin 2 and / or lipocalin 2 degradation product.
(3) The hyaluronic acid production promoter according to (1), wherein the lipocalin family and / or lipocalin family degradation product is β-lactoglobulin and / or β-lactoglobulin degradation product.
(4) The hyaluronic acid production promoter according to (2), wherein the lipocalin 2 degradation product has a molecular weight of 300 or more and 8000 or less.
(5) The hyaluronic acid production promoter according to (2), wherein the lipocalin 2 degradation product is obtained by degrading lipocalin 2 with a proteolytic enzyme.
(6) The hyaluron according to (5), wherein the proteolytic enzyme is at least one selected from trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease. Acid production promoter.
(7) A supplement containing the hyaluronic acid production promoter according to any one of (1) to (6).
(8) Food / beverage products which mix | blended the hyaluronic acid production promoter in any one of (1)-(6).
(9) A cosmetic comprising the hyaluronic acid production promoter according to any one of (1) to (6).

本発明により、リポカリンファミリータンパク質及び/またはリポカリンファミリータンパク質分解物を有効成分とすることで安全性を向上させたヒアルロン酸産生促進剤を提供することができる。   ADVANTAGE OF THE INVENTION By this invention, the hyaluronic acid production promoter which improved the safety | security by using lipocalin family protein and / or lipocalin family protein degradation product as an active ingredient can be provided.

リポカリン2によるヒアルロン酸産生促進効果を示す。The hyaluronic acid production promotion effect by lipocalin 2 is shown. リポカリン2がヒアルロン酸合成酵素遺伝子(Has2)のmRNA発現へ及ぼす影響について比較したものである。This compares the effects of lipocalin 2 on mRNA expression of the hyaluronic acid synthase gene (Has2).

本発明のヒアルロン酸産生促進剤の特徴は、リポカリン2及び/またはリポカリン2をタンパク質分解酵素で分解して得られるリポカリン2分解物を有効成分とすることにある。本発明のリポカリン2はどのような由来のものであっても使用可能である。たとえば、ヒト及びウシ由来のリポカリン2はすでにその遺伝子配列が明らかになっており、遺伝子組換えによる生産が可能であるが、本発明では、遺伝子工学的手法により生産されたリポカリン2も使用可能であり、細胞培養の培養液から回収した細胞由来のものも使用可能である。また、リポカリン2はウシ初乳中に含有されており、乳から回収したものであっても良く、生乳や粉乳、脱脂乳、還元乳等から、加熱処理、加塩処理、エタノール処理、イオン交換クロマトグラフィーやゲル濾過クロマトグラフィー等の各種クロマト処理、限外濾過処理等によって取得することも可能である。   The hyaluronic acid production promoter of the present invention is characterized in that lipocalin 2 and / or lipocalin 2 degradation product obtained by degrading lipocalin 2 with a proteolytic enzyme is an active ingredient. The lipocalin 2 of the present invention can be used from any origin. For example, the lipocalin 2 derived from human and bovine has already been clarified in gene sequence and can be produced by gene recombination, but in the present invention, lipocalin 2 produced by genetic engineering techniques can also be used. In addition, cells derived from the cell culture medium can also be used. Lipocalin 2 is contained in bovine colostrum and may be recovered from milk. From raw milk, powdered milk, skim milk, reduced milk, etc., heat treatment, salting treatment, ethanol treatment, ion exchange chromatography can be used. It can also be obtained by various chromatographic treatments such as chromatography and gel filtration chromatography, ultrafiltration treatment and the like.

リポカリン2分解物は、任意の方法で精製したリポカリン2をトリプシン、パンクレアチン、キモトリプシン、ペプシン、パパイン、カリクレイン、カテプシン、サーモライシン、V8プロテアーゼ等のタンパク質分解酵素で分子量が8,000以下となるように限定分解したペプチド混合物を使用することが可能である。但し、分子量の下限は300以上であることが好ましい。   The lipocalin 2 degradation product is a lipocalin 2 purified by an arbitrary method so as to have a molecular weight of 8,000 or less with a protease such as trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease. It is possible to use limited peptide mixtures. However, the lower limit of the molecular weight is preferably 300 or more.

本発明のヒアルロン酸産生促進剤は、経口投与あるいは塗布することにより、ヒアルロン酸産生促進効果を発揮する。本発明のヒアルロン酸産生促進剤を経口投与するに際しては、有効成分であるリポカリン2あるいはリポカリン2分解物をそのままの状態で用いることもできるが、常法に従い、粉末剤、顆粒剤、錠剤、カプセル剤、ドリンク剤等に製剤化して用いることもできる。本発明において、粉末剤、顆粒剤、錠剤、カプセル剤等の経口剤は、例えば、澱粉、乳糖、白糖、マンニット、カルボキシメチルセルロース、コーンスターチ、無機塩類等の賦形剤を用いて常法によって製剤化することが可能である。この種の製剤には、前記賦形剤の他に、結合剤、崩壊剤、界面活性剤、滑沢剤、流動性促進剤、着色料、香料等を適宜使用してもよい。結合剤としては、例えば、澱粉、デキストリン、アラビアガム、ゼラチン、ヒドロキシプロピルスターチ、カルボキシメチルセルロースナトリウム、メチルセルロース、結晶性セルロース、エチルセルロース、ポリビニルピロリドンが挙げられ、崩壊剤としては、例えば、澱粉、ヒドロキシプロピルスターチ、カルボキシメチルセルロース、カルボキシメチルセルロースナトリウム、架橋カルボキシメチルセルロースナトリウム、結晶性セルロース等が挙げられる。また、界面活性剤としては、大豆レシチン、蔗糖脂肪酸エステル等、滑沢剤としては、タルク、ロウ、蔗糖脂肪酸エステル、水素添加植物油等、流動性促進剤としては無水ケイ酸、乾燥水酸化アルミニウム、ケイ酸マグネシウム等が挙げられる。
さらには、これらのリポカリン2やリポカリン2分解物をそのままあるいは製剤化した後、これをサプリメント、栄養剤や飲食品等に配合することも可能である。なお、リポカリン2あるいはリポカリン2分解物は、比較的熱に対して安定であるので、リポカリン2あるいはリポカリン2分解物を含む原料を通常行われるような条件で加熱殺菌することも可能である。
The hyaluronic acid production promoter of the present invention exhibits hyaluronic acid production promoting effect by oral administration or application. When the hyaluronic acid production promoter of the present invention is orally administered, the active ingredient lipocalin 2 or lipocalin 2 degradation product can be used as it is, but according to conventional methods, powders, granules, tablets, capsules It can also be used in the form of pharmaceutical preparations, drink preparations, etc. In the present invention, oral preparations such as powders, granules, tablets and capsules are formulated by conventional methods using excipients such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, and inorganic salts. It is possible to In this type of preparation, a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a colorant, a fragrance, and the like may be used as appropriate in addition to the excipient. Examples of the binder include starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, sodium carboxymethylcellulose, methylcellulose, crystalline cellulose, ethylcellulose, and polyvinylpyrrolidone. Examples of the disintegrant include starch, hydroxypropyl starch. Carboxymethyl cellulose, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose and the like. In addition, as surfactant, soybean lecithin, sucrose fatty acid ester, etc., as lubricant, talc, wax, sucrose fatty acid ester, hydrogenated vegetable oil, etc., as fluidity promoter, silicic anhydride, dry aluminum hydroxide, Examples include magnesium silicate.
Furthermore, these lipocalin 2 and lipocalin 2 degradation products can be blended in supplements, nutrients, foods and drinks, etc. as they are or after preparation. Since lipocalin 2 or a lipocalin 2 degradation product is relatively stable to heat, it is possible to heat sterilize the raw material containing the lipocalin 2 or the lipocalin 2 degradation product under conditions that are usually performed.

本発明のヒアルロン酸産生促進剤を塗布するに際しては、その使用目的に応じて、通常用いられる公知の成分に配合することによって、液剤、固形剤、半固形剤等の各種剤形に調製することが可能で、好ましい組成物として軟膏、ゲル、クリーム、スプレー剤、貼付剤、ローション、粉末等が挙げられる。例えば、本発明のヒアルロン酸産生促進剤をワセリン等の炭化水素、ステアリルアルコール、ミリスチン酸イソプロピル等の高級脂肪酸低級アルキルエステル、ラノリン等の動物性油脂、グリセリン等の多価アルコール、グリセリン脂肪酸エステル、モノステアリン酸、ポリエチレングリコール等の界面活性剤、無機塩、ロウ、樹脂、水及び、要すればパラオキシ安息香酸メチル、パラオキシ安息香酸ブチル等の保存料に混合することによって、ヒアルロン酸産生促進用化粧料や医薬品を製造することができる。   When applying the hyaluronic acid production promoter of the present invention, various dosage forms such as liquids, solids, semisolids, etc. are prepared by blending with commonly known components according to the purpose of use. Preferred compositions include ointments, gels, creams, sprays, patches, lotions, powders and the like. For example, the hyaluronic acid production promoter of the present invention is a hydrocarbon such as petrolatum, higher fatty acid lower alkyl esters such as stearyl alcohol, isopropyl myristate, animal fats such as lanolin, polyhydric alcohols such as glycerin, glycerin fatty acid esters, mono Cosmetics for promoting hyaluronic acid production by mixing with surfactants such as stearic acid and polyethylene glycol, inorganic salts, waxes, resins, water and, if necessary, preservatives such as methyl paraoxybenzoate and butyl paraoxybenzoate And can produce medicines.

本発明のヒアルロン酸産生促進剤の経口投与による有効量は、その製剤形態、投与方法、使用目的、及びこれを適用される患者の年齢、体重、病状により適宜規定され一定でないが、ラットを用いた動物実験の結果、リポカリン2及び/またはリポカリン2分解物は、ラット体重1kg当たり10μg以上摂取させることでヒアルロン酸産生促進作用を示すことが明らかとなった。したがって、外挿法によると、通常、成人一人当たり一日10μg以上のリポカリン2及び/またはリポカリン2分解物を摂取すればヒアルロン酸産生促進効果が期待できるため、この必要量を確保できるよう飲食品に配合するか、あるいは、医薬として投与すれば良い。なお、投与は必要に応じて一日数回に分けて行うことも可能である。   The effective amount of the hyaluronic acid production promoter of the present invention by oral administration is appropriately defined by the formulation form, administration method, purpose of use, and age, weight, and medical condition of the patient to which it is applied. As a result of animal experiments, it has been clarified that lipocalin 2 and / or lipocalin 2 degradation products exhibit hyaluronic acid production promoting action when ingested at least 10 μg per kg of rat body weight. Therefore, according to the extrapolation method, ingestion of 10 μg or more of lipocalin 2 and / or lipocalin 2 degradation product per adult per day can be expected to promote hyaluronic acid production. Or may be administered as a medicine. The administration can be divided into several times a day as necessary.

本発明のヒアルロン酸産生促進剤の塗布による有効量は、剤形により異なるが、適用する組成物全量を基準として、好ましくは、0.001〜2重量%となるように、リポカリン2及び/またはリポカリン2分解物を配合すれば良い。ただし、入浴剤のように使用時に希釈されるものは、さらに配合量を増やすことができる。   The effective amount by application of the hyaluronic acid production promoter of the present invention varies depending on the dosage form, but preferably, lipocalin 2 and / or so as to be 0.001 to 2% by weight based on the total amount of the composition to be applied. What is necessary is just to mix | blend lipocalin 2 decomposition product. However, what is diluted at the time of use like a bath agent can increase a compounding quantity further.

以下、実施例および試験例を示し、本発明をさらに詳しく説明する。実施例および試験例における「%」は断らない限り「重量%」を意味するものとする。
以下に、実施例及び試験例を示して本発明を詳細に説明するが、これらは単に本発明の実施態様を例示するのみであり、本発明はこれらによって何ら限定されるものではない。
Hereinafter, the present invention will be described in more detail with reference to examples and test examples. “%” In Examples and Test Examples means “% by weight” unless otherwise specified.
EXAMPLES Hereinafter, the present invention will be described in detail with reference to examples and test examples. However, these are merely examples of the present invention, and the present invention is not limited to these examples.

Sセファロース 3,000g を充填したカラムを脱イオン水で充分洗浄し、脱脂乳10,000Lを通液して、脱イオン水で充分洗浄した後、0.1〜1.0Mの塩化ナトリウムの直線濃度勾配で溶出した。その後、リポカリン2を含む溶出画分を再度フェニルSセファロース疎水性カラムクロマトグラフィーで分画した。さらに、この画分をHPLCシステムにてC4およびC8逆相クロマトグラフィー、ゲルろ過クロマトグラフィーで順次処理し、リポカリン2400mg(画分A)を得た。なお、このようにして得られたリポカリン2は、そのままヒアルロン酸産生促進剤として使用可能である。   A column packed with 3,000 g of S Sepharose was thoroughly washed with deionized water, passed through 10,000 L of skimmed milk, thoroughly washed with deionized water, and then a straight line of 0.1 to 1.0 M sodium chloride. Elute with a gradient. Thereafter, the eluted fraction containing lipocalin 2 was fractionated again by phenyl S Sepharose hydrophobic column chromatography. Furthermore, this fraction was sequentially treated with C4 and C8 reverse phase chromatography and gel filtration chromatography using an HPLC system to obtain 2400 mg of lipocalin (fraction A). In addition, the lipocalin 2 obtained in this way can be used as a hyaluronic acid production promoter as it is.

実施例1で得られた画分A25mgを、水100mlに懸濁し、最終濃度が1%となるようにパンクレアチンを加え、37℃で5分から6時間、酵素処理を行った。そして、90℃で5分間加熱処理して酵素を失活させた後、凍結乾燥して、リポカリン2分解物24mg(画分B、C、D)を得た。なお、このようにして得られたリポカリン2分解物の平均分子量は、Bが約8,000、Cが約500、Dが約300であった。また、実施例1で得られた画分A25mgを、水100mlに懸濁し、最終濃度が0.01%となるようにペプシンを添加し、pHを2〜3に調整した後、37℃で12時間酵素処理を行い、さらにpHを8に調整した後、最終濃度が0.01%となるようにトリプシンを添加し、37℃で12時間酵素処理を行った。そして、90℃で5分間加熱処理して酵素を失活させた後、凍結乾燥し、リポカリン2分解物24mg(画分E)を得た。画分B、C、D、Eは、そのままヒアルロン酸産生促進剤として使用可能である。   Fraction A 25 mg obtained in Example 1 was suspended in 100 ml of water, pancreatin was added to a final concentration of 1%, and enzyme treatment was performed at 37 ° C. for 5 minutes to 6 hours. And after heat-processing at 90 degreeC for 5 minute (s), the enzyme was deactivated, it lyophilized | freeze-dried and 24 mg (fractions B, C, D) of lipocalin 2 degradation products were obtained. The average molecular weight of the lipocalin 2 degradation product thus obtained was about 8,000 for B, about 500 for C, and about 300 for D. Further, 25 mg of fraction A obtained in Example 1 was suspended in 100 ml of water, pepsin was added so that the final concentration was 0.01%, the pH was adjusted to 2 to 3, and then 12 ° C at 37 ° C. After carrying out enzyme treatment for a time and adjusting the pH to 8, trypsin was added so that the final concentration was 0.01%, and the enzyme treatment was carried out at 37 ° C. for 12 hours. And after heat-processing at 90 degreeC for 5 minute (s) and deactivating an enzyme, it lyophilized | freeze-dried and 24 mg (fraction E) of lipocalin 2 degradation products were obtained. Fractions B, C, D, and E can be used as hyaluronic acid production promoters as they are.

[試験例1]
実施例1で得られた試料A及び実施例2で得られた試料B乃至Eについて、ラットを用いた動物実験によりヒアルロン酸産生促進作用を調べた。7週齢のWistar系雄ラットを、生理食塩水投与群(対照群)、実施例1で得られた試料Aをラット体重1kg当たり10μg投与する群(A−1群)、実施例1で得られた試料Aをラット体重1kg当たり100μg投与する群(A−2群)、実施例2で得られた試料B乃至Dをラット体重1kg当たり10μg投与する群(B−1〜E−1群)、実施例2で得られた試料B乃至Dをラット体重1kg当たり100μg投与する群(B−2〜E−2群)の11試験群(n=6)に分け、それぞれを毎日1回ゾンデで経口投与して10週間飼育した。皮膚のヒアルロン酸量については、試験前日に剃毛したラットを屠殺後速やかに回収した皮膚組織(各300mg)を測定に供した。加熱によりタンパク変性させた皮膚組織をアクチナーゼによりタンパク質分解した。得られた分解物を、更にヒアルロニダーゼにてヒアルロン酸に分解した。ヒアルロン酸をHPLC法にて測定した。
その結果を表1に示す。
[Test Example 1]
Sample A obtained in Example 1 and Samples B to E obtained in Example 2 were examined for hyaluronic acid production promoting action by animal experiments using rats. 7-week-old Wistar male rats were obtained in the physiological saline-administered group (control group), the sample A obtained in Example 1 was administered in 10 μg per kg body weight of the rat (Group A-1), and in Example 1. Group (A-2 group) administered with 100 μg of the obtained sample A per kg body weight of the rat, group (B-1 to E-1 group) administered with 10 μg of the samples B to D obtained in Example 2 per kg of the rat body weight The samples B to D obtained in Example 2 were divided into 11 test groups (n = 6) in the group (B-2 to E-2 group) administered with 100 μg per kg of the body weight of the rat, and each was sampled once a day with a sonde. Orally administered and reared for 10 weeks. Regarding the amount of hyaluronic acid in the skin, skin tissues (each 300 mg) collected immediately after sacrifice of the shaved rat on the day before the test were subjected to measurement. The skin tissue denatured by heating was proteolyzed with actinase. The obtained decomposition product was further decomposed into hyaluronic acid with hyaluronidase. Hyaluronic acid was measured by HPLC method.
The results are shown in Table 1.

Figure 0006259208
Figure 0006259208

この結果、10週間後の可溶性画分中ヒアルロン酸量は、対照群に比べ、すべての試験群で有意に高い値を示した。このことから、リポカリン2及び/又はリポカリン2分解物には、ヒアルロン酸産生促進作用があることが明らかとなり、ヒアルロン酸産生促進剤として有用であることが示された。また、このヒアルロン酸産生促進作用はリポカリン2及び/又はリポカリン2分解物をラット体重1kg当たり少なくとも10.0μg投与した場合に認められることが明らかとなった。 As a result, the amount of hyaluronic acid in the soluble fraction after 10 weeks was significantly higher in all test groups than in the control group. From this, it was clarified that lipocalin 2 and / or lipocalin 2 degradation products have a hyaluronic acid production promoting action, indicating that it is useful as a hyaluronic acid production promoter. In addition, it has been clarified that this hyaluronic acid production promoting action is observed when lipocalin 2 and / or lipocalin 2 degradation product is administered at least 10.0 μg / kg body weight of the rat.

[試験例2]
実施例1で得られた試料A及び実施例2で得られた試料B、C、Dについて、正常ヒト線維芽細胞株〔白人女性の皮膚より採取されたCCD45SK(ATCCRL 1506)〕を用いた実験によりヒアルロン酸産生促進作用を調べた。10容量%ウシ胎児血清(以下FBSと略記)含有変法イーグル培地(MEM、10‐101、大日本製薬社製)を用いて、正常ヒト線維芽細胞株を4×10個/ウエル/0.4mlとなるように24ウエルプレートに播種して、5%炭酸ガス、飽和水蒸気下、37℃で24時間培養した後、0.6容量%FBS含有MEM培地に置換した。そして、実施例1で得られた試料A及び実施例2で得られた試料B、C、Dを、各ウエルに0.1容量%となるように添加(n=6)して、72時間培養して培養液を得た。このようにして得られた培養液中の、ヒアルロン酸量(バイオテック トレーディング パートナーズ社製)を測定した。なお、対照として、リポカリン2又はリポカリン2分解物を添加しないで同様の試験を行った。その結果を表2に示す。
[Test Example 2]
Experiments using sample A obtained in Example 1 and samples B, C, and D obtained in Example 2 using a normal human fibroblast cell line [CCD45SK (ATCCRL 1506) collected from white female skin] The hyaluronic acid production promoting effect was examined by the above. Using a modified Eagle's medium (MEM, 10-101, manufactured by Dainippon Pharmaceutical Co., Ltd.) containing 10% by volume fetal bovine serum (hereinafter abbreviated as FBS), 4 × 10 4 normal human fibroblast cell lines / well / 0 After seeding in a 24-well plate so as to be 4 ml and culturing at 37 ° C. under 5% carbon dioxide gas and saturated steam for 24 hours, the medium was replaced with a 0.6 volume% FBS-containing MEM medium. Then, the sample A obtained in Example 1 and the samples B, C, and D obtained in Example 2 were added to each well so as to be 0.1% by volume (n = 6), and 72 hours Culture was obtained by culturing. The amount of hyaluronic acid (manufactured by Biotech Trading Partners) in the thus obtained culture broth was measured. As a control, the same test was performed without adding lipocalin 2 or lipocalin 2 degradation product. The results are shown in Table 2.

Figure 0006259208
Figure 0006259208

表2の結果、リポカリン2及び/又はリポカリン2分解物を添加した群は、リポカリン2及び/又はリポカリン2分解物を添加していない群(対照)に比べていずれも2倍以上のヒアルロン酸産生促進能を示した。このことから、リポカリン2及び/又はリポカリン2分解物には、皮膚線維芽細胞に働きかけ、ヒアルロン酸産生を促進する作用があることが明らかとなり、ヒアルロン酸産生促進剤として有用であることが示された。 As a result of Table 2, hyaluronic acid production in the group to which lipocalin 2 and / or lipocalin 2 degradation product was added was more than twice that of the group to which lipocalin 2 and / or lipocalin 2 degradation product was not added (control). It showed the ability to promote. This reveals that lipocalin 2 and / or lipocalin 2 degradation products have an action of acting on dermal fibroblasts and promoting hyaluronic acid production, and are shown to be useful as hyaluronic acid production promoters. It was.

[試験例3]
市販のヒトリポカリン2リコンビナントタンパク質(NGAL)(PROSPEC社)、及び正常ヒト新生児包皮皮膚線維芽細胞(NHDF(NB))を用いた細胞実験により、リポカリン2によるヒアルロン酸産生促進作用について調べた。NHDF(NB)細胞を12穴プレートに0.5×10cells/wellになる様に播種し、MEDIUM106培地(GIBCO社製)にて37℃、5%CO環境下にて3日間培養した。NGALが10nMなるようにMEDIUM106培地に溶解したものを培養した細胞に添加し、24時間培養した。このようにして得られた培養液のヒアルロン酸量をヒアルロン酸測定キットQnE Hyaluronic Acid(HA)Quantitatve ELISA assay(Biotech Trading Partners社製)にて測定した。その結果を図1に示す。
[Test Example 3]
The hyaluronic acid production promoting action of lipocalin 2 was examined by a cell experiment using a commercially available human lipocalin 2 recombinant protein (NGAL) (PROSPEC) and normal human neonatal foreskin skin fibroblasts (NHDF (NB)). NHDF (NB) cells were seeded in a 12-well plate at 0.5 × 10 5 cells / well and cultured in MEDIUM 106 medium (GIBCO) at 37 ° C. in a 5% CO 2 environment for 3 days. . What was melt | dissolved in MEDIUM106 culture medium so that NGAL might be 10 nM was added to the cultured cell, and it culture | cultivated for 24 hours. The amount of hyaluronic acid in the culture solution thus obtained was measured with a hyaluronic acid measurement kit QnE Hyaluronic Acid (HA) Quantitative ELISA assay (manufactured by Biotech Trading Partners). The result is shown in FIG.

この結果、コントロールと比較し、NGALを添加したサンプルは、ヒアルロン酸量が有意に増加したことから、リポカリン2がヒアルロン酸産生を促進することか確認された。  As a result, it was confirmed that lipocalin 2 promotes hyaluronic acid production in the sample to which NGAL was added as compared with the control because the amount of hyaluronic acid was significantly increased.

[試験例4]
リポカリン2がヒアルロン酸合成酵素遺伝子(Has2)のmRNA発現へ及ぼす影響について、リアルタイムPCR法を用いて検討した。具体的には、NHDF(NB)細胞を24穴プレートに0.5×10cells/wellになる様に播種し、MEDIUM106培地(GIBCO社製)にて37℃、5%CO環境下にて3日間培養した。3日間の培養期間のうち、NGALを10nMになるようにMEDIUM106培地に溶解したものを、それぞれ2時間、4時間、6時間、9時間、12時間、24時間細胞に添加・保持した後、以下の手順でtotal RNAを回収しcDNAを合成した。
培養した細胞にRNA抽出剤であるISOGEN(ニッポンジーン社製)を0.5ml添加し5分間静置した後、ピペッティングにて可溶化させた細胞液を1.5ml容のチューブに回収した。細胞液に0.1mlのクロロホルムを添加し、十分に攪拌した後、二層に分離した上層(水層)を新たな1.5ml容のチューブに回収した。回収液に0.25mlの2−プロピルアルコールを添加し、10分間静置後、15,000rpm、4℃の条件にて15分間遠心分離し、total RNAの沈殿物を得た。得られた沈殿物を、70%エタノールにて洗浄した後、DEPC水に溶解しRNA液とした。1μg分のRNAからTakara PrimeScriptTM RT reagent Kitを用いてcDNAを合成した。得られたcDNAをテンプレートとして、SYBR Green(Takara SYBR Prime Ex TaqII)を使用したリアルタイムPCRを行った。反応条件は、95℃、30秒の初期変性後、95℃、5秒の変性、57℃、15秒のアニーリング、72℃、20秒の伸張であり、合計40サイクル反応させた。プライマーは表3に記載のHas2遺伝子発現確認用プライマーを使用した。結果を図2に示す。
[Test Example 4]
The effect of lipocalin 2 on mRNA expression of the hyaluronic acid synthase gene (Has2) was examined using a real-time PCR method. Specifically, NHDF (NB) cells were seeded in a 24-well plate at 0.5 × 10 5 cells / well, and were placed in MEDIUM 106 medium (GIBCO) at 37 ° C. in a 5% CO 2 environment. For 3 days. After 3 days of culture period, NGAL dissolved in MEDIUM106 medium to 10 nM was added to and retained in cells for 2 hours, 4 hours, 6 hours, 9 hours, 12 hours and 24 hours, respectively. Total RNA was recovered by the procedure described above and cDNA was synthesized.
To the cultured cells, 0.5 ml of ISOGEN (manufactured by Nippon Gene) as an RNA extractant was added and allowed to stand for 5 minutes, and then the cell solution solubilized by pipetting was collected in a 1.5 ml tube. After 0.1 ml of chloroform was added to the cell solution and stirred sufficiently, the upper layer (aqueous layer) separated into two layers was collected in a new 1.5 ml tube. 0.25 ml of 2-propyl alcohol was added to the recovered solution, left standing for 10 minutes, and then centrifuged for 15 minutes at 15,000 rpm and 4 ° C. to obtain a total RNA precipitate. The obtained precipitate was washed with 70% ethanol and then dissolved in DEPC water to obtain an RNA solution. CDNA was synthesized from 1 μg of RNA using Takara PrimeScript RT reagent Kit. Real-time PCR using SYBR Green (Takara SYBR Prime Ex TaqII) was performed using the obtained cDNA as a template. The reaction conditions were 95 ° C., 30 seconds of initial denaturation, 95 ° C., 5 seconds of denaturation, 57 ° C., 15 seconds of annealing, 72 ° C., 20 seconds of extension, for a total of 40 cycles. Primers for confirming Has2 gene expression shown in Table 3 were used as primers. The results are shown in FIG.

Figure 0006259208
Figure 0006259208

図2により、NGALをNHDF(NB)細胞に添加した時に、Has2遺伝子のmRNA発現量は、4時間で有意に亢進し、その後12時間までゆるやかに減弱し、24時間で対照群との差は見られなくなった。     As shown in FIG. 2, when NGAL was added to NHDF (NB) cells, the mRNA expression level of Has2 gene was significantly increased at 4 hours and then gradually attenuated to 12 hours, and at 24 hours, the difference from the control group was I can no longer see it.

表4に示す配合のヒアルロン酸産生促進用飲料を常法により製造した。製造した飲料の風味は良好で沈殿等の問題もなかった。 Beverages for promoting hyaluronic acid production with the formulation shown in Table 4 were produced by conventional methods. The flavor of the produced beverage was good and there were no problems such as precipitation.

Figure 0006259208
Figure 0006259208

表5に示す配合のドウを常法により作製し、成形した後、焙焼してヒアルロン酸産生促進用ビスケットを製造した。 A dough having the composition shown in Table 5 was produced by a conventional method, molded, and then baked to produce hyaluronic acid production-promoting biscuits.

Figure 0006259208
Figure 0006259208

表6に示す配合のヒアルロン酸産生促進剤を常法により製造した。 Hyaluronic acid production promoters having the composition shown in Table 6 were produced by a conventional method.

Figure 0006259208
Figure 0006259208

表7に示す配合の化粧水を常法により製造した。 A lotion having the composition shown in Table 7 was produced by a conventional method.

Figure 0006259208
Figure 0006259208

表8に示す配合のクリームを常法により製造した。 A cream having the composition shown in Table 8 was produced by a conventional method.

Figure 0006259208
Figure 0006259208

[試験例5]
実施例6で得られた化粧水及び実施例7で得られたクリームを用いて、実使用テストを行った。比較品としては、リポカリン2及び/又はリポカリン2分解物を除いた以外は実施例6及び7と同じ配合のものを用いた。顔面のたるみや小ジワが認められる乾燥肌を有する成人女性20人を、それぞれ10人ずつ無作為に2群(A、B群)に、また、手に肌荒れが認められる女性20人を、それぞれ10人ずつ無作為に2群(C、D群)に分け、A群の顔面には本発明品の化粧水2gを、B群の顔面には比較品の化粧水2gを、C群の手指には本発明品のクリーム2gを、D群の手指には比較品のクリーム2gを、それぞれ1日2回通常の使用状態と同様に10日間塗布した。結果を表9に示す。
[Test Example 5]
Using the lotion obtained in Example 6 and the cream obtained in Example 7, an actual use test was conducted. As a comparative product, the same formulation as in Examples 6 and 7 was used except that lipocalin 2 and / or lipocalin 2 degradation product was excluded. 20 adult women with dry skin where facial sagging and fine wrinkles are recognized, 10 people each randomly into 2 groups (Groups A and B), and 20 women with rough skin on the hands, respectively 10 people randomly divided into 2 groups (Group C, D), 2g of the product of the present invention was applied to the face of Group A, 2g of the comparison product was applied to the face of Group B, and fingers of Group C 2 g of the product of the present invention and 2 g of the comparative product were applied to the fingers of group D twice a day for 10 days in the same manner as in normal use. The results are shown in Table 9.

Figure 0006259208
Figure 0006259208

表9の結果より、本発明品の化粧水は、比較品の化粧水に比べて、乾燥感の改善、肌荒れ等の改善が顕著であり、ヒアルロン酸産生促進効果に優れていることが実証された。また、本発明品のクリームについても、比較品のクリームに比べて、乾燥感の改善、肌荒れに顕著な改善がみられ、肌荒れ等の自然増悪抑制効果を有することが明らかとなった。
[試験例6]
変形性関節炎による軽度の痛みを有する患者20名を対象に、実施例3の飲料を1日1回100g飲用し、1年間の臨床試験を行った。関節の疼痛および機能の評価を、疼痛に対するビジュアルアナログスケール(VAS)、及び、関節炎の関節における疼痛、機能、および硬直に関するWestern Ontario and McMaster Universities(WOMAC)指標にて変形性関節症の評価を行った。結果を表10に示す。
From the results in Table 9, it was demonstrated that the skin lotion of the present invention has a significant improvement in dry feeling and rough skin compared with the skin lotion of the comparative product, and is excellent in hyaluronic acid production promoting effect. It was. In addition, the cream of the present invention also has an improvement in dry feeling and a marked improvement in rough skin, as compared with the comparative cream, and has been found to have an effect of suppressing natural deterioration such as rough skin.
[Test Example 6]
For 20 patients with mild pain due to osteoarthritis, 100 g of the beverage of Example 3 was drunk once a day, and a one-year clinical trial was conducted. Assess joint pain and function with visual analog scale (VAS) for pain and with the Western Ontario and McMaster Universities (WOMAC) index for pain, function and stiffness in arthritic joints It was. The results are shown in Table 10.

Figure 0006259208
Figure 0006259208

本発明は、皮膚の荒れ、シワ、弾性低下、関節機能低下等を防止するのに有用なヒアルロン酸産生促進剤、ヒアルロン酸産生促進用サプリメント、飲食品及びヒアルロン酸産生促進用化粧料に関する。 The present invention relates to hyaluronic acid production promoters, hyaluronic acid production promoting supplements, foods and drinks, and hyaluronic acid production promoting cosmetics that are useful for preventing rough skin, wrinkles, reduced elasticity, reduced joint function, and the like.

Claims (6)

リポカリン2及び/又はリポカリン2分解物を有効成分とするヒアルロン酸産生促進剤。 A hyaluronic acid production promoter comprising lipocalin 2 and / or lipocalin 2 degradation product as an active ingredient. 前記リポカリン2分解物が、分子量300以上、8000以下であることを特徴とする請求項1に記載のヒアルロン酸産生促進剤。 The hyaluronic acid production promoter according to claim 1, wherein the lipocalin 2 degradation product has a molecular weight of 300 or more and 8000 or less. 前記リポカリン2分解物が、リポカリン2をタンパク質分解酵素で分解して得られたものであることを特徴とする請求項2に記載のヒアルロン酸産生促進剤。 The hyaluronic acid production promoter according to claim 2, wherein the lipocalin 2 degradation product is obtained by degrading lipocalin 2 with a proteolytic enzyme. 前記タンパク質分解酵素が、トリプシン、パンクレアチン、キモトリプシン、ペプシン、パパイン、カリクレイン、カテプシン、サーモライシン、V8プロテアーゼから選択されるいずれか1種以上であることを特徴とする請求項3に記載のヒアルロン酸産生促進剤。 The hyaluronic acid production according to claim 3, wherein the proteolytic enzyme is at least one selected from trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease. Accelerator. 請求項1〜4のいずれかに記載のヒアルロン酸産生促進剤を配合したヒアルロン酸産生促進用サプリメント。 The supplement for hyaluronic acid production promotion which mix | blended the hyaluronic acid production promoter in any one of Claims 1-4. 請求項1〜4のいずれかに記載のヒアルロン酸産生促進剤を配合したヒアルロン酸産生促進用飲食品。

The food-drinks for hyaluronic acid production promotion which mix | blended the hyaluronic acid production promoter in any one of Claims 1-4.

JP2013126446A 2013-06-17 2013-06-17 Hyaluronic acid production promoter Active JP6259208B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2013126446A JP6259208B2 (en) 2013-06-17 2013-06-17 Hyaluronic acid production promoter
PCT/JP2014/066000 WO2014203883A1 (en) 2013-06-17 2014-06-17 Hyaluronic acid production promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013126446A JP6259208B2 (en) 2013-06-17 2013-06-17 Hyaluronic acid production promoter

Publications (2)

Publication Number Publication Date
JP2015000038A JP2015000038A (en) 2015-01-05
JP6259208B2 true JP6259208B2 (en) 2018-01-10

Family

ID=52104615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013126446A Active JP6259208B2 (en) 2013-06-17 2013-06-17 Hyaluronic acid production promoter

Country Status (2)

Country Link
JP (1) JP6259208B2 (en)
WO (1) WO2014203883A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6259209B2 (en) * 2013-06-17 2018-01-10 雪印メグミルク株式会社 Collagen production promoter
JP6259207B2 (en) * 2013-06-17 2018-01-10 雪印メグミルク株式会社 Elastin production promoter
JP5866053B1 (en) * 2014-12-15 2016-02-17 株式会社ファンケル Skin viscoelastic marker and use thereof
JP2016124852A (en) * 2015-01-08 2016-07-11 雪印メグミルク株式会社 Hyaluronic acid production promoter

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903584D0 (en) * 1999-02-18 1999-04-07 Univ Leeds Modified calycins
EP1280909A2 (en) * 2000-05-12 2003-02-05 Lexicon Genetics Incorporated Human lipocalin homologs and polynucleotides encoding the same
CA2425761C (en) * 2000-10-13 2005-11-15 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
US20030147830A1 (en) * 2002-01-30 2003-08-07 The Procter & Gamble Company Topical skin and/or hair compositions containing protein
AU2003247303A1 (en) * 2002-07-17 2004-02-02 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
PL2571510T3 (en) * 2010-05-21 2019-03-29 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
IN2014DN03449A (en) * 2011-11-30 2015-06-05 Meiji Co Ltd
JP6259209B2 (en) * 2013-06-17 2018-01-10 雪印メグミルク株式会社 Collagen production promoter
JP6259207B2 (en) * 2013-06-17 2018-01-10 雪印メグミルク株式会社 Elastin production promoter

Also Published As

Publication number Publication date
JP2015000038A (en) 2015-01-05
WO2014203883A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
JP6259209B2 (en) Collagen production promoter
JP6259207B2 (en) Elastin production promoter
AU2012215805B2 (en) Skin collagen production promoter
JP6259208B2 (en) Hyaluronic acid production promoter
JP2024045248A (en) Collagen production accelerator
JP4698935B2 (en) Skin collagen production promoter
KR101789355B1 (en) Skin collagen production-promoting agent
JP5955499B2 (en) Skin collagen production promoter
JP6522286B2 (en) Hyaluronic acid production promoter
JP5955631B2 (en) Hyaluronic acid production promoter
JP5955630B2 (en) Hyaluronic acid production promoter
JP5955632B2 (en) Hyaluronic acid production promoter
JP2010229118A (en) Lipase inhibitor
JP2016124852A (en) Hyaluronic acid production promoter
JP2018188395A (en) Chondrogenesis promotion composition
NZ614185B2 (en) Skin collagen production promoter

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170411

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20170411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171208

R150 Certificate of patent or registration of utility model

Ref document number: 6259208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250